Your browser is no longer supported. Please, upgrade your browser.
EIDX Eidos Therapeutics, Inc. daily Stock Chart
Eidos Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.31 Insider Own1.10% Shs Outstand38.01M Perf Week-2.07%
Market Cap1.88B Forward P/E- EPS next Y-2.78 Insider Trans-1.15% Shs Float12.42M Perf Month-1.77%
Income-48.90M PEG- EPS next Q-0.58 Inst Own33.00% Short Float15.78% Perf Quarter4.12%
Sales26.70M P/S70.46 EPS this Y44.60% Inst Trans-0.11% Short Ratio20.18 Perf Half Y-15.85%
Book/sh4.60 P/B10.49 EPS next Y-12.10% ROA-26.80% Target Price56.43 Perf Year21.17%
Cash/sh5.04 P/C9.57 EPS next 5Y28.00% ROE-30.50% 52W Range28.00 - 66.56 Perf YTD-15.93%
Dividend- P/FCF- EPS past 5Y- ROI-21.60% 52W High-28.18% Beta-
Dividend %- Quick Ratio17.00 Sales past 5Y- Gross Margin90.60% 52W Low70.71% ATR2.75
Employees47 Current Ratio17.00 Sales Q/Q- Oper. Margin- RSI (14)51.03 Volatility4.15% 6.05%
OptionableYes Debt/Eq0.09 EPS Q/Q-85.10% Profit Margin- Rel Volume0.13 Prev Close48.25
ShortableYes LT Debt/Eq0.09 Earnings- Payout- Avg Volume97.14K Price47.80
Recom2.10 SMA20-0.76% SMA502.45% SMA200-1.93% Volume1,651 Change-0.93%
May-14-20Downgrade JP Morgan Overweight → Neutral $58 → $50
Apr-01-20Resumed BofA/Merrill Neutral $51
Feb-20-20Initiated Guggenheim Buy $66
Feb-18-20Downgrade Barclays Equal Weight → Underweight $45
Nov-01-19Downgrade Barclays Overweight → Equal Weight $37 → $45
Jul-22-19Initiated Piper Jaffray Overweight $55
Feb-27-19Upgrade JP Morgan Neutral → Overweight
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Oct-31-18Initiated ROTH Capital Buy
Jul-16-18Initiated JP Morgan Overweight $36
Jul-16-18Initiated BofA/Merrill Neutral $24
Jul-16-18Initiated Barclays Overweight $32
Jul-05-20 03:05PM  
Jul-01-20 08:38AM  
Jun-10-20 09:13PM  
May-08-20 04:30PM  
Apr-07-20 05:19PM  
Mar-31-20 04:52PM  
Mar-19-20 10:29AM  
Feb-26-20 04:30PM  
Feb-05-20 09:15AM  
Dec-12-19 03:14PM  
Dec-06-19 08:00AM  
Nov-18-19 09:00AM  
Nov-16-19 07:28PM  
Oct-31-19 04:30PM  
Oct-28-19 05:14PM  
Oct-21-19 05:22PM  
Oct-14-19 07:30AM  
Oct-11-19 09:27AM  
Sep-30-19 07:00AM  
Sep-19-19 08:00AM  
Sep-16-19 08:03AM  
Sep-12-19 06:50PM  
Sep-10-19 11:39AM  
Sep-03-19 12:15PM  
Aug-29-19 09:16PM  
Aug-16-19 04:22PM  
Aug-14-19 08:00AM  
Aug-12-19 04:42PM  
Aug-09-19 07:19AM  
Aug-01-19 04:30PM  
Jul-15-19 07:11AM  
Jul-01-19 06:02AM  
Jun-18-19 08:00AM  
Jun-03-19 12:45PM  
May-30-19 07:12PM  
May-27-19 01:24AM  
May-09-19 07:59PM  
May-07-19 08:21PM  
Apr-19-19 08:00AM  
Apr-15-19 08:30AM  
Apr-05-19 03:40PM  
Apr-03-19 04:20PM  
Apr-02-19 12:22PM  
Apr-01-19 09:54PM  
Mar-18-19 09:30AM  
Mar-11-19 08:00AM  
Mar-04-19 09:19AM  
Feb-27-19 07:00AM  
Feb-25-19 08:00AM  
Feb-21-19 08:00AM  
Jan-23-19 06:02PM  
Jan-02-19 01:15PM  
Dec-20-18 10:39PM  
Dec-06-18 04:15PM  
Dec-05-18 10:35AM  
Nov-28-18 01:05PM  
Nov-21-18 08:15AM  
Nov-14-18 08:00AM  
Nov-10-18 10:00AM  
Nov-06-18 04:05PM  
Oct-29-18 08:00AM  
Oct-26-18 08:00AM  
Oct-05-18 09:10AM  
Oct-03-18 02:35PM  
Oct-01-18 01:34PM  
Sep-25-18 08:00AM  
Sep-17-18 08:00AM  
Aug-28-18 08:13AM  
Aug-27-18 02:59PM  
Aug-23-18 08:00AM  
Aug-07-18 04:30PM  
Jul-13-18 02:45PM  
Jun-28-18 09:07AM  
Jun-25-18 02:37PM  
Jun-22-18 04:05PM  
Jun-20-18 03:11PM  
Jun-19-18 10:49PM  
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fox Jonathan CSee RemarksJul 07Sale50.005,000250,000387,673Jul 09 04:05 PM